Florbetapir Market Size, Share Global Analysis Report, 2020–2026

Industry Insights

The Florbetapir Market report analyzes and notifies the industry statistics at the global as well as regional and country levels in order to acquire a thorough perspective of the entire florbetapir market. The historical and past insights are provided for FY 2016 to FY 2019 whereas projected trends are delivered for FY 2020 to FY 2026. The quantitative and numerical data is represented in value (USD Million) from FY 2016 – 2026.

This specialized and expertise-oriented industry research report scrutinizes the technical and commercial business outlook of the florbetapir industry. The report analyzes and declares the historical and current trends analysis of the florbetapir industry and subsequently recommends the projected trends anticipated to be observed in the florbetapir market during the upcoming years.

Key Insights from Primary Research

• According to the interview with industry participants, the florbetapir market is anticipated to expand at a significant rate over the forecast period i.e. a compound annual growth rate of around 3.6% by 2026 end over 2019 market value
• The North America region was accounted for around half of the market share of total revenue generated in 2019
• FDA approved Amyvid for the application in patients evaluated with cognitive decline especially Alzheimer's disease in April 2012
• Rising prevalence of dementia is the chief reason behind the development of the florbetapir molecule
• Growing geriatric population is also another factor responsible for the growth of the market, especially in the U.S. and Western Europe

Key Recommendations from Analysts

• As per our analyst, Elli Lilly has the monopoly in the florbetapir market as the product has been patented by the company
• Among the product type segment, the 30mL vial segment accounts for more than half of the value share in 2019
• Robust research and development activities and investment in the clinical trials are anticipated to fuel the product demand over the forecast period
• Another factor responsible for the increasing demand for new PET tracers is unavailability efficient technique to diagnose dementia
• Prominent market players of PET scanning molecule such as Eli Lilly, Navidea Biopharmaceuticals, Piramal Healthcare, and GE healthcare focusing on developing new molecule for the early diagnosis of disorders such as Alzheimer's disease and other dementias

Florbetapir (Amyvid) Market Value Share (%) by Region, 2019

The quantitative data is further underlined and reinforced by comprehensive qualitative data which comprises various across-the-board market dynamics. The rationales which directly or indirectly impact the florbetapir industry are exemplified through parameters such as growth drivers, restraints, challenges, and opportunities among other impacting factors.

Throughout our research report, we have encompassed all the proven models and tools of industry analysis and extensively illustrated all the key business strategies and business models adopted in the florbetapir industry. The report provides an all-inclusive and detailed competitive landscape prevalent in the florbetapir market.

The report utilizes established industry analysis tools and models such as Porter’s Five Forces framework to analyze and recognize critical business strategies adopted by various stakeholders involved in the entire value chain of the florbetapir industry.

The report study further includes an in-depth analysis of industry players' market shares and provides an overview of leading players' market position in the florbetapir sector. Key strategic developments in the florbetapir market competitive landscape such as acquisitions & mergers, inaugurations of different products and services, partnerships & joint ventures, MoU agreements, VC & funding activities, R&D activities, and geographic expansion among other noteworthy activities by key players of the florbetapir market are appropriately highlighted in the report.

Research and development activities by major pharmaceutical giants are driving the growth of the market. Prominent market players of PET scanning molecule such as Eli Lilly, Navidea Biopharmaceuticals, Piramal Healthcare, and GE healthcare focusing on developing new molecule for the early diagnosis of disorders such as Alzheimer's disease and other dementias. For instance, Eli Lilly revealed in its recent annual report that flortaucipir, a new molecule used as a PET tracer is in phase three of its clinical trial. Furthermore, pharmaceutical giants such as piramal and GE healthcare also concentrating on developing new molecule on positron emission tomography tracer for early diagnosis of cognitive impairment diseases.

Another factor responsible for the increasing demand for new PET tracers is unavailability efficient technique to diagnose dementia coupled with the rising geriatric population. As per numerous research studies Alzheimer's disease is directly related to aging, as a majority of the Alzheimer's disease cases are more from the age of 65.

The florbetapir market research report delivers an acute valuation and taxonomy of the florbetapir industry by practically splitting the market on the basis of different types, applications, and regions. Through the analysis of the historical and projected trends, all the segments and sub-segments were evaluated through the bottom-up approach, and different market sizes have been projected for FY 2020 to FY 2026. The regional segmentation of the florbetapir industry includes the complete classification of all the major continents including North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Further, country-wise data for the florbetapir industry is provided for the leading economies of the world.

The florbetapir market is segmented based on type and region. On the basis of type segmentation, the market is classified into 30 mL vial and 50 mL vial. In terms of region segmentation, the market is bifurcated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Report Scope

Competitive Players

• Eli Lilly
• Navidea Biopharmaceuticals
• Piramal Healthcare
• GE healthcare

The taxonomy of the florbetapir industry by its scope and segmentation is as follows:

By Type Segmentation Analysis (Customizable)

• 30 mL Vial
• 50 mL Vial

Regional Segmentation Analysis (Customizable)

• North America
  • The U.S.
  • Canada
• Europe
  • Germany
  • The UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of the Middle East & Africa